Thanks to Sydney Valves for the live case invite! Not a candidate for any of our 3 TMVR trials. Valve was 41x25 with severe MAC (not rheumatic) & neoLVOT was 149. Hence the ARCTIC TMVR + LAMPOON. Awesome imaging by Richard Sheu

Day 1 at #ACC25 did not disappoint! 10 major trials dropped today — 3 in NEJM, 1 in Lancet, 1 in JAMA. Here’s your high-yield summary thread: what you need to know, why it matters, and what might change. #CardioTwitter #MedTwitter

🔥 Day 2 at #ACC2025 delivered game-changing insights: Nurse-led ACS care slashes CV events by 30%, liberal fluid intake safe in HF, cerebral protection during TAVR shows no stroke benefit, and clopidogrel beats aspirin post-PCI! See all highlights here 👉 #CardioTwitter

1/ New data on bifurcation PCI The #CRABBIS trial compares two side-branch ballooning strategies after main vessel stenting: •PKP = POT → Kissing Balloon → POT •PSP = POT → Side-branch dilation → POT Which gives better stent geometry? Let’s dig in #CardioTwitter

Social 📊 determinants of health 🏥 play an important role in a variety of populations 👥, including #CAD patients 🏩 undergoing #PCI 🩺. Strong work Sant Kumar 🏆

Systematic intravascular #imaging in all comers, including a large proportion of #CHIP cases, is feasible and still associated with incremental benefit for #PCI over an already high utilization.

Here are 10 reasons NOT to routinely pre-treat NSTE-ACS patients with P2Y12 inhibitors